Copyright ©The Author(s) 2024.
World J Gastroenterol. Feb 28, 2024; 30(8): 806-810
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.806
Figure 1
Figure 1 Unanswered questions about adjuvant therapy for patients with hepatocellular carcinoma following potentially curative resection or local ablation. Questions appear within the pie, and evidence-based responses are written around it. AIT: Adoptive immunotherapy; HAIC: Hepatic arterial infusion chemotherapy; ICI: Immune checkpoint inhibitor; RFS: Recurrence-free survival; TACE: Transarterial chemoembolization; Vp1: Segmental portal vein invasion; Vp2: Right anterior or posterior portal vein invasion.